Biosion Announces the Appointment of Kedan Lin, Ph.D.
Biosion, Inc., a leading clinical-stage biotechnology firm, has made a significant addition to its executive team by appointing Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. Dr. Lin brings over two decades of invaluable experience in biotech research and development, focusing on clinical and regulatory advancements. Her role will be crucial in steering Biosion's innovative therapies forward, continuing the company’s commitment to its notable 'discover-development-partnership' model.
Dr. Lin's Expertise and Previous Roles
Dr. Lin is known for her extensive background in clinical operations, portfolio management, and business development. Before joining Biosion, she served as Senior Vice President of U.S. Operations and Corporate Strategy at Harbour Biomed US, where she successfully directed global clinical development programs and influenced significant business development initiatives. Her broad experience in navigating complex biotech landscapes equips her uniquely for her new responsibilities.
Statements from Leadership
Expressing enthusiasm about Dr. Lin's qualifications, Dr. Mingjiu Chen, Founder and CEO of Biosion, stated, 'We are thrilled to welcome Kedan to our executive team. Her deep expertise in biologics development and strategic alliances will be instrumental in advancing our mission and delivering breakthrough antibody-based therapies to patients globally. Her appointment is a key step in furthering Biosion's strategy and expanding our global footprint.'
Dr. Lin's Vision for the Future
In her new role, Dr. Lin has expressed excitement about joining the team during such a critical phase for the company. 'I am excited to join the Biosion team at this pivotal time,' Dr. Lin remarked. 'I look forward to working alongside the talented team at Biosion to continue advancing innovative therapies that address unmet medical needs, all while strengthening our global impact and helping patients worldwide.'
About Biosion
Biosion is dedicated to the advancement of medicine through the development of innovative antibody-based therapies aimed at improving patient outcomes for those with immune and oncologic diseases. The company utilizes its proprietary technologies, including the H³ antibody discovery platform, SynTracer HT endocytosis platform, and Flexibody bispecific platform. Through these advancements, Biosion aims to create highly differentiated medicines that tackle significant unmet medical needs on a global scale. Employing its renowned 'discover-development-partnership' model, Biosion has established ten collaborations, propelling seven clinical-stage assets, such as monoclonal antibodies and bispecific antibodies, into successful development. The company maintains operations in various regions, including the US, China, and Australia.
Frequently Asked Questions
What is Kedan Lin's new role at Biosion?
Kedan Lin has been appointed as the Chief Development Officer and President of Biosion US.
What experience does Kedan Lin bring to Biosion?
Dr. Lin has over twenty years of expertise in biotech R&D, clinical operations, and business development.
Who made the announcement regarding Dr. Lin's appointment?
The announcement was made by Dr. Mingjiu Chen, the Founder and CEO of Biosion, Inc.
What is Biosion's primary focus as a biotechnology company?
Biosion focuses on developing innovative antibody-based therapies for immune and oncologic diseases.
What innovative technologies does Biosion utilize?
Biosion utilizes proprietary technologies such as the H³ antibody discovery platform and the Flexibody bispecific platform.
